Why NovoCure Limited’s (NVCR) Stock Is Down 5.06%
As of Wednesday, July 29, NovoCure Limited’s NVCR share price has dipped by 5.06%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Commentary & Analysis
Why NovoCure Limited’s (NVCR) Stock Is Down 5.75%
As of Friday, July 24, NovoCure Limited’s NVCR share price has dipped by 5.75%, which has investors questioning if this is right time to buy.Jenna Brashear
Why NovoCure Limited’s (NVCR) Stock Is Up 24.12%
As of Thursday, July 23, NovoCure Limited’s NVCR share price has surged by 24.12%, which has investors questioning if this is right time to sell.Jenna Brashear
What You Need to Know About NovoCure Limited's Q3 Earnings
NovoCure Limited's fiscal Q3 earnings report was released on Thursday, July 23. Let's dive in to see if (NVCR) missed or beat analyst's expectations.Jenna Brashear
Why NovoCure Limited’s (NVCR) Stock Is Up 30.32%
As of Thursday, July 23, NovoCure Limited’s NVCR share price has surged by 30.32%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | NVCR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,773.5 | $334.8 | 52% |
|
| Shares Out (Mil) | 116.0 | 41.7 | 66% |
|
| Institutional Ownership | 89.8% | 77.3% | 58% |
|
| Float (Mil) | 95.8 | 34.7 | 60% |
|
| Beta | 0.93 | 0.86 | 55% |
|
| Avg Daily Volume (000s) | 2,287 | 266 | 84% |
|
| Price Change (52-week) |
33.9% | 60.7% | 72% |
|
| Growth | NVCR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 5.8% | 11.8% | 40% |
|
| Net Income (5yr) | (54.8%) | (5.8%) | 6% |
|
| EPS (5yr) | (54.4%) | 10.7% | 3 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (23.3%) | (16.1%) | 28% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 6 | |
| Current EPS | ($0.245) | ($1.251) | ($0.915) | |
| Month Ago EPS | ($0.327) | ($1.594) | ($1.193) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 2 | 1 | |
| Three Months Ago EPS | ($0.320) | ($1.563) | ($1.157) | |
| Year/Year Chg | 81.5% | 2.4% | (48.2%) | |
| Financials | NVCR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $699 | $152 | 46% |
|
| Net Income (TTM) (Mil) | ($149) | ($11) | 8% |
|
| EPS (TTM) | ($1.308) | ($0.500) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($3) | ($2) | 27% |
|
| Net Cash Flow (TTM) (Mil) | ($49) | $1 | 20% |
|
| Long-Term Debt (Q1) (Mil) | $233 | $22 | 52% |
|
| Enterprise Value (Q1) (Mil) | $1,848 | $304 | 48% |
|
| Valuation | NVCR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.25 | 2.88 | 79% |
|
| P/E | na | 30.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.9 | na |
|
| Ratios | NVCR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 76.4% | 59.1% | 86% |
|
| Net Margin | (21.2%) | (7.7%) | 17% |
|
| ROA | (14.6%) | (13.7%) | 23% |
|
| ROE | (43.2%) | (15.9%) | 17% |
|
| Liabilities to Assets | 57.5% | 44.9% | 51% |
|
| F-Score | 3 | 4 | 19% |
|
NovoCure Limited did not pass any screens on 7/30/2026.
